HC Wainwright began coverage on shares of Aileron Therapeutics (NASDAQ:ALRN) in a research report report published on Monday, Marketbeat reports. The firm issued a buy rating and a $7.00 target price on the stock.
Several other analysts also recently weighed in on ALRN. Zacks Investment Research upgraded Aileron Therapeutics from a hold rating to a buy rating and set a $0.75 target price for the company in a research note on Thursday, December 27th. ValuEngine downgraded Aileron Therapeutics from a buy rating to a hold rating in a research note on Thursday, January 24th.
Shares of NASDAQ:ALRN opened at $1.92 on Monday. Aileron Therapeutics has a twelve month low of $0.52 and a twelve month high of $9.50. The company has a market cap of $27.73 million, a P/E ratio of -1.08 and a beta of 3.18. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.19.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
See Also: Earnings Reports
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.